Korea To Reform Reimbursement Management To Cut Expenditure
Executive Summary
To trim the healthcare financial burden and boost the country’s national health insurance coverage as planned, South Korea will introduce a drug re-evaluation system to adjust prices of both novel and generic drugs, drawing a negative response from the pharma industry.
You may also be interested in...
Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics
South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.
Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics
South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.
Korea May Adopt Further Cost-Containment Steps Under 'Moon Jae-In Care' – IQVIA
Korea is expected to feel the pressure to introduce more drug cost-containment measures amid rapidly rising National Health Insurance expenditures, IQVIA predicts. In particular, expenses associated with implementation of 'Moon Jae-in Care' could erode NHI financial surpluses in the short-medium term.